Literature DB >> 21135421

Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1).

K K C Chan1, K L Lee, P K N Lam, K I Law, G M Joynt, W W Yan.   

Abstract

OBJECTIVE: To report Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of acute respiratory distress syndrome caused by influenza A (H1N1).
DESIGN: Multi-centred, retrospective observational study.
SETTING: Intensive care units in Hong Kong. PATIENTS: Recipients of extracorporeal membrane oxygenation for confirmed influenza A (H1N1) infection from 1 May 2009 to 28 February 2010. MAIN OUTCOME MEASURE: Hospital mortality.
RESULTS: During the study period, 120 patients were mechanically ventilated in intensive care units, among whom seven received veno-venous extracorporeal membrane oxygenation. The median (interquartile range) age of the latter patients was 42 (39-50) years, four had various chronic illnesses and one had a body mass index of greater than 30 kg/m². The median (interquartile range) time from symptom onset to hospital admission was 5 (4-7) days. Corresponding values for the duration of extracorporeal membrane oxygenation, mechanical ventilation, intensive care unit stay, and hospital stay were 6 (6-10), 19 (11-25), 19 (18-30), and 31 (25-55) days, respectively. One patient died (hospital mortality, 14%) and six made full recoveries. All seven patients received oseltamivir; in addition three received intravenous zanamivir, four received convalescent plasma, and one received hyperimmune immunoglobulin. Nosocomial infection was the commonest complication. There was no life- or limb-threatening complication directly attributable to extracorporeal membrane oxygenation.
CONCLUSION: In response to the pandemic of influenza A (H1N1), some intensive care units in Hong Kong were able to offer extracorporeal membrane oxygenation to selected cases. In this small series, patient outcomes were similar to those reported in other observational studies, indicating that intensive care units in Hong Kong are capable of successfully introducing this technology. However, the cost-effectiveness and optimal delivery of this strategy remain uncertain.

Entities:  

Mesh:

Year:  2010        PMID: 21135421

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  12 in total

Review 1.  Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era.

Authors:  Graeme MacLaren; Alain Combes; Robert H Bartlett
Journal:  Intensive Care Med       Date:  2011-12-07       Impact factor: 17.440

2.  ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure.

Authors:  Salvatore Grasso; Pierpaolo Terragni; Alberto Birocco; Rosario Urbino; Lorenzo Del Sorbo; Claudia Filippini; Luciana Mascia; Antonio Pesenti; Alberto Zangrillo; Luciano Gattinoni; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2012-02-10       Impact factor: 17.440

Review 3.  Extracorporeal membrane oxygenation in the pre and post lung transplant period.

Authors:  Nirmal S Sharma; Mathew G Hartwig; Don Hayes
Journal:  Ann Transl Med       Date:  2017-02

Review 4.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 5.  Extracorporeal gas exchange for acute respiratory failure in adult patients: a systematic review.

Authors:  Matthieu Schmidt; Carol Hodgson; Alain Combes
Journal:  Crit Care       Date:  2015-03-16       Impact factor: 9.097

6.  A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease.

Authors:  Mengyao Sun; Yinghui Xu; Hua He; Li Zhang; Xu Wang; Qing Qiu; Chao Sun; Ye Guo; Shi Qiu; Kewei Ma
Journal:  Int J Infect Dis       Date:  2020-07-04       Impact factor: 3.623

Review 7.  Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome.

Authors:  Charles-Édouard Luyt; Alain Combes; Jean-Louis Trouillet; Ania Nieszkowska; Jean Chastre
Journal:  Presse Med       Date:  2011-11-16       Impact factor: 1.228

Review 8.  Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.

Authors:  H Cliff Sullivan; John D Roback
Journal:  Transfus Med Rev       Date:  2020-04-23

Review 9.  The epidemiological and public health research response to 2009 pandemic influenza A(H1N1): experiences from Hong Kong.

Authors:  Peng Wu; Benjamin J Cowling; Joseph T Wu; Eric H Y Lau; Dennis K M Ip; Hiroshi Nishiura
Journal:  Influenza Other Respir Viruses       Date:  2012-08-09       Impact factor: 4.380

Review 10.  The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.

Authors:  John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck
Journal:  J Infect Dis       Date:  2014-07-16       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.